MLTX — MOONLAKE IMMUNOTHERAPEUTICS

Ownership history in Caption Management, LLC  ·  16 quarters on record

This page tracks every 13F SEC filing in which Caption Management, LLC reported a position in MOONLAKE IMMUNOTHERAPEUTICS (MLTX). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.

Peak position
0.33% (2023 Q3)
Avg. % of fund
0.07%
First filed
2023 Q3
Last filed
2025 Q3
Quarters held
16
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q3 REDUCED 90,800 -159,000 -63.7% 0.01% $651K $7.17
2025 Q3 REDUCED 249,800 -145,400 -36.8% 0.01% $1.8M $7.17
2025 Q3 ADDED 395,200 +99,500 +33.6% 0.02% $2.8M $7.17
2025 Q2 ADDED 295,700 +289,731 +4853.9% 0.15% $14.0M $47.20
12 older quarters hidden  —  Sign in free or upgrade to Premium to see full history
% of Fund (quarterly)    MLTX price (monthly, adj. close)

Other funds also holding MLTX

As of 2025 Q4 — sorted by position size

BVF INC/IL 3Y 7Y 8.76% Lion Point Capital, LP 3Y 7Y 4.6% Cormorant Asset Management, LP 3Y 7Y 2.65% Logos Global Management LP 3Y 1.39% Deep Track Capital, LP 3Y 1.08% Vivo Capital, LLC 3Y 7Y 0.85% STEMPOINT CAPITAL LP 0.79% Eagle Health Investments LP 3Y 0.54% ACUTA CAPITAL PARTNERS, LLC 3Y 7Y 0.53% Rhenman & Partners Asset Management AB 3Y 7Y 0.45%
← Back to Caption Management, LLC Holdings